Skip to main content
. 2023 Mar 9;11:1108756. doi: 10.3389/fpubh.2023.1108756

Table 2.

The outcome of the meta-analysis.

Outcomes Number T/C End of treatment
WMD/RR/SMD 95%CI Heterogeneity P -value F/R GRADE
Ginger vs. placebo
VAS 3 88/100 WMD = −1.21 (−2.34)–(−0.08) 66.0% P = 0.036 R Low
Adverse events 3 112/116 RR = 1.57 (0.63)–(3.91) 0.0% P = 0.336 R Very low
Number of vomiting 2 56/65 WMD = 0.05 (−0.23)–(0.32) 0.0% P = 0.743 R Low
Effective rate 3 96/100 RR = 1.68 (1.09)–(2.57) 76.4% P = 0.018 R Low
Ginger vs. CM
Number of vomiting 3 87/95 SMD = 0.30 (−0.12)–(0.73) 51.1% P = 0.160 R Low
Rhodes index 2 62/60 WMD = −0.52 (−0.79)–(−0.24) 0.0% P ≤ 0.001 R Moderate
Adverse events 4 76/77 RR = 0.21 (0.05)–(0.96) 87.2% P = 0.045 R Low
AP vs. placebo
Effective rate 6 429/420 RR = 1.25 (0.94)–(1.65) 88.0% P = 0.124 R Low
AP vs. CM
Effective rate 3 105/105 RR = 1.55 (1.30)–(1.86) 0.0% P ≤ 0.001 R Low
Number of anti-emetic drug 2 75/76 SMD = −0.44 (−0.77)–(−0.11) 0.0% P = 0.008 R Low
AT vs. CM
Effective rate 3 115/115 RR = 1.71 (1.02)–(2.86) 80.8% P = 0.042 R Low

WMD, weighted mean difference; SMD, standard mean difference; RR, risk ratio; CI, confidence interval; VAS, visual analog scale; P, P-value represents clinical significance; CM, conventional medicine; AP, acupressure treatment; AT, acupuncture treatment; T, test group; C, control group; F, Fixed effects model; R, Random effects model; GRADE, Grades of Recommendation, Assessment, Development, and Evaluation; Very low, very low quality; Low, low quality; Moderate, Moderate quality.

High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.